Hormone Refractory Breast Cancer Market

Hormone Refractory Breast Cancer Market – Overview

The global hormone refractory breast cancer market is anticipated to develop at a favorable rate from 2021 to 2031 (forecast period). The number of people who have hormone refractory breast cancer is increasing around the world. Hormone refractory breast cancer, also known as hormone resistant breast cancer, is described as a condition wherein the breast cancer does not react or remains ineffective to hormonal therapy. Most advanced breast cancers become hormone refractory to some degree.

The global increase in breast cancer is a major aspect projected to drive the global hormone refractory breast cancer market. Moreover, the growing need for early diagnosis and the increased focus on research & development efforts by key companies is expected to boost the global hormone refractory breast cancer market.

Hormone Refractory Breast Cancer Market – Competitive Landscape

Key players active in the global hormone refractory breast cancer market are AstraZeneca plc., Bioenvision Limited, Neopharm Ltd., AmpliMed Corporation, Bluefish Pharmaceuticals AB, F. Hoffman-La Roche Ltd., NeoCorp GmbH, and Boehringer Ingelheim GmbH.

Key players are focusing on strategic activities such as new product development, collaborations, mergers and acquisitions, and global expansion.

Hormone Refractory Breast Cancer Market – Trends and Opportunities

Breast cancer is among the most common types of malignant cancers in women over the age of 40. As per the World Health Organization (WHO) estimates, breast cancer was responsible for around 685 000 deaths worldwide in 2020. Hormone therapies are used to treat breast cancer, which leads to resistance after long-term usage of hormone therapy. This resistance to hormone therapy is known as hormone refractory breast cancer. As a result, there is a growing demand for effective therapy in the global hormone refractory breast cancer market.

Since no conventional therapy is approved for hormone refractory breast cancer, the global hormone refractory breast cancer market has enormous future potential. However, there is a growing likelihood that approved medicines will be available in the near future, as medications such as everolimus and trastuzumab, either alone or in combination, are being developed for the effective therapy of hormone refractory breast cancers.

The rising worldwide prevalence of breast cancer, increasing incidence rate of hormone refractory breast cancer, and an aging population are expected to boost the global hormone refractory breast cancer market. Moreover, increased demand for advanced treatments and strong R&D expenditure in breast cancer medications is anticipated to propel the global hormone refractory breast cancer market. Furthermore, a significant number of new chemical entities (NCEs) in various clinical trial stages are likely to arise in the near future, which is expected to provide growth prospects to the worldwide hormone refractory breast cancer market during the forecast period.

Hormone Refractory Breast Cancer Market – Regional Landscape

The hormone refractory breast cancer market in Asia Pacific is projected to grow due to the significant growth of the healthcare and pharmaceutical industries and the increased spending power of the region's service providers. Moreover, the regional market is likely to benefit from rapidly growing economies and the growth of medical tourism in nations like China and India. Such factors are expected to boost the growth of hormone refractory breast cancer market in Asia Pacific during the forecast period.

The North America hormone refractory breast cancer market is anticipated to witness considerable growth due to the increased prevalence of breast cancer, high acceptance of hormonal therapy, and modern healthcare facilities. Moreover, the existence of a high number of drug developers in North America is expected to promote the expansion of the global hormone refractory breast cancer market during the forecast period.

The hormone refractory breast cancer market in Latin America is projected to experience growth during the forecast period. Regulatory approvals for novel treatments are expected to generate prospects for drug researchers and players in the hormone refractory breast cancer market in Latin America.